Oruka Therapeutics (NASDAQ: ORKA) insider transactions

In the twelve months to 10 November 2026, executives and directors of Oruka Therapeutics reported 127 open-market sales of 4,075,142 shares ($340.1m) and 0 open-market purchases, by 7 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Oruka Therapeutics shares reported on Form 4
Date	Insider	Role	Transaction	Shares	Price	Held after	Filing
2 November 2026	Klein Lawrence Otto	Chief Executive Officer	Option exercise, 10b5-1 plan	+25,000	$7.80	948,128	Form 4
2 November 2026	Klein Lawrence Otto	Chief Executive Officer	Open-market sale, 10b5-1 plan	−6,466	$94.77	941,662	Form 4
2 November 2026	Klein Lawrence Otto	Chief Executive Officer	Open-market sale, 10b5-1 plan	−15,036	$95.64	926,626	Form 4
2 November 2026	Klein Lawrence Otto	Chief Executive Officer	Open-market sale, 10b5-1 plan	−2,442	$96.70	924,184	Form 4
2 November 2026	Klein Lawrence Otto	Chief Executive Officer	Open-market sale, 10b5-1 plan	−756	$97.45	923,428	Form 4
2 November 2026	Klein Lawrence Otto	Chief Executive Officer	Open-market sale, 10b5-1 plan	−300	$98.40	923,128	Form 4
20 October 2026	Quinlan Paul T	General Counsel	Option exercise, 10b5-1 plan	+9,000	$7.80	38,995	Form 4
20 October 2026	Quinlan Paul T	General Counsel	Open-market sale, 10b5-1 plan	−400	$74.90	38,595	Form 4
20 October 2026	Quinlan Paul T	General Counsel	Open-market sale, 10b5-1 plan	−500	$76.12	38,095	Form 4
20 October 2026	Quinlan Paul T	General Counsel	Open-market sale, 10b5-1 plan	−1,000	$77.21	37,095	Form 4
20 October 2026	Quinlan Paul T	General Counsel	Open-market sale, 10b5-1 plan	−4,100	$78.79	32,995	Form 4
20 October 2026	Quinlan Paul T	General Counsel	Open-market sale, 10b5-1 plan	−3,000	$79.49	29,995	Form 4
15 October 2026	Goncalves Joana	Chief Medical Officer	Option exercise, 10b5-1 plan	+3,500	$6.84	35,271	Form 4
15 October 2026	Goncalves Joana	Chief Medical Officer	Option exercise, 10b5-1 plan	+3,500	$7.80	38,771	Form 4
15 October 2026	Goncalves Joana	Chief Medical Officer	Open-market sale, 10b5-1 plan	−2,853	$73.89	35,918	Form 4
15 October 2026	Goncalves Joana	Chief Medical Officer	Open-market sale, 10b5-1 plan	−1,847	$74.69	34,071	Form 4
15 October 2026	Goncalves Joana	Chief Medical Officer	Open-market sale, 10b5-1 plan	−1,400	$75.48	32,671	Form 4
15 October 2026	Goncalves Joana	Chief Medical Officer	Open-market sale, 10b5-1 plan	−700	$76.67	31,971	Form 4
15 October 2026	Goncalves Joana	Chief Medical Officer	Open-market sale, 10b5-1 plan	−200	$77.71	31,771	Form 4
12 October 2026	Agarwal Arjun	Senior Vice President, Finance	Option exercise, 10b5-1 plan	+8,541	$12.50	22,760	Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Oruka Therapeutics page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.